Showing results (31-40 of 36) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
JCO Precision Oncology|November 10, 2022
Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver MetastasesFederica Marmorino, Michele Prisciandaro, Mirella Giordano, et al.European Journal of Cancer (Oxford, England : 1990)|August 8, 2021
Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 studyCarlotta Antoniotti, W Michael Korn, Federica Marmorino, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2023
An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal CancerCarlotta Antoniotti, Alessandra Boccaccino, Robert Seitz, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONODaniele Rossini, Carlotta Antoniotti, Sara Lonardi, et al.JCO Precision Oncology|October 5, 2020
Intratumoral Transcriptome Heterogeneity Is Associated With Patient Prognosis and Sidedness in Patients With Colorectal Cancer Treated With Anti-EGFR Therapy From the CO.20 TrialElisa Fontana, Gift Nyamundanda, David Cunningham, et al.The Lancet. Oncology|May 31, 2022
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trialCarlotta Antoniotti, Daniele Rossini, Filippo Pietrantonio, et al.Pageof 4